=0%, p=0.56). The confidence interval of most studies crossesthe vertical line of null effect (mean difference equal to zero),indicating that the majority of these studies did not find astatistically significant difference between DCS+CBT and placebo+CBT. Conclusions: D-cycloserine has a neutral effect on enhancingcognitive-behavioral therapy in the treatment of obsessive compulsive disorder in randomized controlled trials. The present results fail to support the use of D-cycloserine with cognitive behavioral therapy for obsessive compulsive disorder.
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Clinical profiles of obsessive compulsive symptoms in schizophrenic patients
Min-Seong Koo, Kwandong University School of Medicine, Republic of Korea
Abstract Purpose: We also investigated the differences in the psychotic symptoms and suicidality between patients with schizophrenia who did or did not have OCD. Methods: Seventy-one subjects with the DSM-IV diagnosis of schizophrenia were evaluated by the Structured Clinical Interview for DSM-IV Axis I disorders, the Yale-Brown Obsessivecompulsive Scale and the Positive and Negative Syndrome Scale Results: The OCD patients with schizophrenia were 20 (28.2%) among 71 subjects. The 20 subjects with OCD had significantly more severe negative and total psychotic symptoms evaluated with PANSS than subjects without OCD. The schizophrenia with OCD had significant higher recent suicidal attempt rate than the subjects without OCD.
Conclusions:
The results of this study suggest the possibility that OCD symptoms in schizophrenia may be related to negative symptoms and the OC symptoms may be related to the impulsivity expressed as suicidal attempts.
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Changes , OCD patients underwent SRI-based pharmacotherapy for next 4 months and were also assessed for their changed profile of clinical symptomatology with MRI re-scanning. Cortical and subcortical brain structures were reconstructed from individual T1WI and were subsequently parcellated into 64 cortical regions and 14 subcortical regions bilateral, to calculate individualized grey matter (GM) structural covariance matrices. Furthermore, individualized white matter (WM) network matrices of streamline density between these 82 regions were reconstructed by way of deterministic tractography method from DWI images. Finally, graph theory analyses for these individualized, weighed GM or WM matrices were conducted. Results: All of the individualized WM connectome as well as GM connectome [with sparsity level matched with those of WM connectome per individual] satisfied small-worldness and modular structure. After 4 months of pharmacotherapy, statistically significant (p < .05) group by time interactions of eigenvector centrality value were revealed in the left pars triangularis, rostral anterior cingulate and caudal middle frontal cortices, precuneus, transverse temporal cortex, putamen and right cuneus for individualized cortical surface area & subcortical volume structural covariance network; in the left medial orbitofrontal, precentral and supramarginal cortices for individualized cortical thickness & subcortical volume structural covariance network; and in right pallidum as well as in left caudal anterior cingulate and transverse temporal cortices for individualized WM fiber density network, respectively. Conclusions: This study reported pharmacotherapy-related changes of regional network characteristic for individualized GM structural covariance as well as WM fiber density network in OCD patients. 
Abstract

Objectives:
Over the past few decades, the complex treatment of chronic back pain includes a psychosomatic approach, focusing on the biopsychosocial model of chronic pain. Namely, a comprehensive assessment of physical, neurological and psychological state, their mutual influence and selection of therapy, that focuses on these characteristics.
